文献速递类风湿关节炎

第三代抗环瓜氨酸肽抗体改善类风湿关节炎风险人群临床关节炎预测

Third-Generation Anti-Cyclic Citrullinated Peptide Antibodies Improve Prediction of Clinical Arthritis in Individuals at Risk of Rheumatoid Arthritis.
PubMed 文献 · Arthritis Rheumatol · 2020-09-07

该研究在347例抗CCP2阳性且无临床滑膜炎的高危个体中检测抗CCP3抗体,发现抗CCP3可改善炎症性关节炎的预测,尤其在高滴度抗CCP2个体中风险分层价值显著。

要点

  • 抗CCP3在抗CCP2阳性风险人群中多呈阴性或强阳性,低滴度少见。
  • 抗CCP3阴性时,低及高滴度抗CCP2组进展率分别降至3.3%和9.8%。
  • 抗CCP3强阳性时,高滴度抗CCP2组进展率升至48.4%。

核心结论

  • 抗CCP3抗体可改善抗CCP2阳性风险个体向炎症性关节炎进展的预测。
  • 抗CCP3状态对高滴度抗CCP2个体的风险分层影响尤为显著。

研究设计与样本

  • 研究纳入347例抗CCP2阳性且无临床滑膜炎的风险个体,检测库存血清抗CCP3抗体。
  • 进展分析仅纳入至少一次随访的291例受试者,以≥1个关节出现临床滑膜炎定义进展。

主要发现

  • 347例中抗CCP3阴性138例(39.7%),强阳性189例(54.4%),低滴度20例(5.7%)。
  • 抗CCP2低滴度103例(29.7%)。
  • 抗CCP3阴性时,低滴度抗CCP2组进展率从7.5%降至3.3%,高滴度组从38.9%降至9.8%。
  • 抗CCP3强阳性时,高滴度抗CCP2组进展率从38.9%升至48.4%。

关键数值与推荐

  • 抗CCP2预测进展的AUC为0.72(95%CI 0.66, 0.78),抗CCP3为0.76(95%CI 0.70, 0.81)。
  • 多变量分析中抗CCP3阳性者进展为炎症性关节炎的OR为1.73(95%CI 1.20, 2.51)(P < 0.01)。

临床怎么用

  • 对无临床滑膜炎的抗CCP2阳性风险个体,可检测抗CCP3以细化炎症性关节炎风险分层。
  • 高滴度抗CCP2且抗CCP3强阳性者进展风险较高,抗CCP3阴性者风险相对较低。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To 1) determine the prevalence of anti-cyclic citrullinated peptide 3 (anti-CCP3) antibodies in anti-CCP2 antibody-positive (anti-CCP2+) at-risk individuals, and 2) explore the additional value of anti-CCP3 antibodies in anti-CCP2+ at-risk individuals for predicting progression to inflammatory arthritis. METHODS: Stored serum samples obtained from 347 anti-CCP2+ (BioPlex 2200; Bio-Rad) at-risk individuals without clinical synovitis were tested for anti-CCP3 antibodies. Anti-CCP2 titers were categorized as low or high, and anti-CCP3 titers were categorized as negative, low, or strong. Progression to inflammatory arthritis was defined as the development of clinical synovitis in ≥1 joint. Only subjects with ≥1 follow-up visit were included in the progression analysis (n = 291). RESULTS: In the 347 samples included, anti-CCP3 antibody titers tended to be either negative (n = 138 [39.7%]) or strongly positive (n =189 [54.4%]), with very few subjects showing a low titer (n = 20 [5.7%]). In contrast, for anti-CCP2 antibodies, more low titers were observed (n = 103 [29.7%]). Eighty-eight of 291 subjects (30.2%) developed inflammatory arthritis. The rate of progression to inflammatory arthritis in the low-titer anti-CCP2 group and the high-titer anti-CCP2 group fell from 7.5% to 3.3% and from 38.9% to 9.8%, respectively, when anti-CCP3 was negative. Progression in the high-titer anti-CCP2 group increased from 38.9% to 48.4% when anti-CCP3 was strongly positive. The area under the curve was 0.72 for anti-CCP2 (95% confidence interval [95% CI] 0.66, 0.78) and 0.76 for anti-CCP3 (95% CI 0.70, 0.81) for assessment of progression. In the multivariable analysis, the odds ratio for the development of inflammatory arthritis in anti-CCP3+ subjects was 1.73 (95% CI 1.20, 2.51) (P < 0.01). CONCLUSION: Anti-CCP3 antibodies improve the prediction of inflammatory arthritis in anti-CCP2+ at-risk individuals. The impact of anti-CCP3 antibody status for the risk stratification of individuals with high-titer anti-CCP2 is particularly notable.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Di Matteo A, Mankia K, Duquenne L, et al. Third-Generation Anti-Cyclic Citrullinated Peptide Antibodies Improve Prediction of Clinical Arthritis in Individuals at Risk of Rheumatoid Arthritis. Arthritis Rheumatol. 2020. PMID: 32840033. doi:10.1002/art.41402

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。